Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897090 | 1.00 | CYP2A6 (0.55) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL28566065 | 0.86 | CYP2A6 (0.52) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL31425881 | 0.86 | CYP2A6 (0.52) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL8255589 | 0.86 | CYP2A6 (0.52) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL9314600 | 0.84 | CA2 (0.53) | CA2MAPTKEAP1NFE2L2MTNR1A | |
| SCHEMBL8253326 | 0.84 | CYP2A6 (0.50) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL7116432 | 0.83 | KEAP1 (0.69) | CYP2A6CA2MAPTKEAP1NFE2L2 | |
| SCHEMBL7429693 | 0.82 | KEAP1 (0.68) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL28563290 | 0.81 | CYP2A6 (0.64) | CYP2A6CA2HDAC10HDAC11HDAC8 | |
| SCHEMBL12749691 | 0.81 | MTNR1A (0.52) | MAPTKEAP1NFE2L2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CYP2A6 105/4885CA2 1832/4885HDAC10 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.